• Lamotrigine in Fundamental Channelopathy Research: Chemical

  2026-08-05

  Explore Lamotrigine’s detailed chemical profile and its nuanced action as a sodium channel blocker and serotonin inhibitor. This article uniquely bridges molecular pharmacology with advanced channelopathy research, offering granular workflow guidance for experimental rigor.

• Pyroptosis Genes and GSDMC Targeting in Pancreatic Adenocarc

  2026-08-05

  Yan et al. constructed a prognostic model for pancreatic adenocarcinoma based on pyroptosis-related gene expression, identifying GSDMC as a novel therapeutic target. Their systems analysis also highlights FGFR/VEGFR pathway inhibition as a promising therapeutic avenue, with practical implications for individualized cancer treatment strategies.

• (R)-MG132: The Gold Standard Negative Control for Proteasome

  2026-08-04

  (R)-MG132, the stereoisomeric MG-132 enantiomer, is revolutionizing mechanistic studies by providing unambiguous negative control in proteasome assays. Its near-inert profile ensures precise discrimination between on-target and off-target effects in ubiquitin-proteasome system research, empowering cancer metabolism studies with unprecedented rigor.

• Central Brain-to-Spinal Circuits in Opioid-Induced Pain Adap

  2026-08-04

  Yin et al. (2024) identified a central brain-to-spinal opioid pathway governing morphine-induced mechanical hypersensitivity and analgesic tolerance in mice. This work shifts the mechanistic focus from peripheral to central circuits, providing new targets for mitigating opioid-induced side effects and informing future pain research.

• Sex-Dependent Immune Effects of SAG in CNS Demyelination Mod

  2026-08-03

  This study demonstrates that the Smoothened receptor agonist SAG modulates peripheral immune responses and myelin regeneration differently in male and female demyelination models. The findings provide mechanistic insight into Hedgehog pathway activation and its interplay with androgens, highlighting important considerations for sex-specific therapeutic strategies.

• 0.4% Trypan Blue Solution: Technical Use in Cell Viability A

  2026-08-03

  0.4% Trypan Blue Solution provides a robust method for distinguishing live and dead cells in cell culture and cytotoxicity assays. It supports accurate cell viability measurement through membrane-impermeable staining, but is strictly intended for research—not diagnostic or clinical—applications.

• Calpain Inhibition Restores Cognition After Maternal Surgery

  2026-08-02

  A recent Neuropharmacology study demonstrates that excessive calpain activation following maternal non-obstetric surgery impairs offspring cognitive function by disrupting BDNF/TrkB-mediated synaptic plasticity. Postnatal calpain inhibition using MDL 28170 partially reversed these deficits, highlighting a mechanistic link and a potential therapeutic strategy for neurodevelopmental protection.

• BCECF-AM: Optimizing Intracellular pH Measurement in Live Ce

  2026-08-01

  BCECF-AM enables precise, ratiometric mapping of intracellular pH dynamics across plant, animal, and microbial systems. This guide translates recent protocol innovations into actionable workflows for live-cell imaging, revealing troubleshooting insights and comparative advantages for protein secretion research.

• ACE2 Activation by Diminazene Aceturate Counters Sepsis Card

  2026-07-31

  This study demonstrates that pharmacological activation of ACE2 by Diminazene Aceturate protects against sepsis-induced cardiomyopathy in mice through MasR-Sirt1-mediated mitochondrial biogenesis. The findings clarify a mechanistic pathway for cardiac protection in sepsis and provide a foundation for targeted investigation of mitochondrial dysfunction in septic cardiac injury.

• Bortezomib (PS-341): Applied Workflows in Proteasome Researc

  2026-07-31

  Bortezomib (PS-341) enables precise, reversible inhibition of the 20S proteasome, unlocking nuanced studies of apoptosis and proteostasis in disease models. This guide presents stepwise experimental enhancements and troubleshooting strategies, with direct application to neurodegeneration and cancer workflows.

• FK866 (APO866): NAMPT Inhibition and the Evolution of Host-D

  2026-07-30

  Explore the unique mechanism and advanced applications of FK866 (APO866), a potent NAMPT inhibitor, in hematologic cancer research. This article connects emerging immunometabolic insights to practical assay design, offering a scientifically distinct perspective.

• VX-661 and Calnexin: Shaping the Future of CFTR Modulation

  2026-07-30

  This thought-leadership article explores the mechanistic foundations and translational strategies surrounding VX-661, a leading F508del CFTR corrector, with a focus on calnexin-dependent rescue in cystic fibrosis research. By integrating recent deep mutational scanning evidence with actionable workflow recommendations, the piece provides a blueprint for precision CFTR modulation, surpassing typical product descriptions and charting a course toward next-generation, variant-sensitive therapeutic development.

• CD28-ARS2 Axis Drives PKM2 Splicing for CD8+ T Cell Flexibil

  2026-07-29

  The referenced study reveals how the CD28-ARS2 signaling axis in CD8+ T cells orchestrates alternative splicing of pyruvate kinase (PKM), favoring the PKM2 isoform and enabling metabolic flexibility crucial for antitumor immunity. This mechanistic insight advances understanding of immunometabolic reprogramming and offers new avenues for optimizing cancer immunotherapy strategies.

• VE-821 ATR Kinase Inhibitor: Applied Workflows & Troubleshoo

  2026-07-29

  VE-821 offers unrivaled selectivity and potency as an ATR kinase inhibitor, empowering DNA repair, radiosensitization, and combination therapy workflows. This article delivers stepwise experimental strategies, troubleshooting insights, and cross-domain applications, grounded in recent research and optimized for translational impact.

• mTORC1-IRE1α Pathway Drives Palmitate-Induced Hepatocyte Lip

  2026-07-28

  This study reveals that palmitate-induced activation of the mTORC1-IRE1α pathway in hepatocytes is a key driver of triglyceride overproduction and cell death. Inhibiting this pathway, including with mTOR inhibitors such as Rapamycin, prevents lipotoxicity, providing a mechanistic basis for targeting mTORC1-IRE1α in metabolic liver disease.

15349 records 1/1024 page Next 12345 下5页 Last page